A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators.
Multiple trials using antiarrhythmic drugs, pharmacologic therapy, and implantable cardioverter defibrillators have been performed in an attempt to improve survival in patients: (1) postmyocardial infarction; (2) with congestive heart failure, with and without nonsustained ventricular tachycardia; and (3) with sustained ventricular tachycardia and those who have survived an out-of-hospital cardiac arrest. This article reviews some of the key findings and limitations of completed and ongoing trials. We also make recommendations for the current treatment of such patients based on the results of these trials.
Naccarelli
G V
GV
Section of Cardiology and Cardiovascular Center, Penn State University College of Medicine, Hershey, USA.
Wolbrette
D L
DL
Dell'Orfano
J T
JT
Patel
H M
HM
Luck
J C
JC
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017147:Defibrillators, Implantable; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy*; D017180:Tachycardia, Ventricular / Q000628:therapy*
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents